{
    "clinical_study": {
        "@rank": "117878", 
        "brief_summary": {
            "textblock": "To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma\n      concentration range comparable to that obtained after currently used oral dosages of\n      itraconazole oral solution; and to obtain preliminary safety data in patients with advanced\n      HIV disease."
        }, 
        "brief_title": "Study of Itraconazole in Patients With Advanced HIV Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will receive intravenous itraconazole solution twice daily for 2 days and then once\n      daily for five additional days. Patients then randomized to receive twice-daily or\n      once-daily itraconazole oral solution for an additional 28 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        Antiretroviral therapy providing patient has already been on a stable, unchanged regimen\n        for 8 weeks prior to study entry.\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 lymphocyte count < 300 cells/mm3.\n\n          -  No clinically significant abnormalities, elicited by history and physical\n             examination.\n\n          -  No clinically significant abnormalities in blood count, biochemical profile, or\n             urinalysis within 2 weeks of study entry.\n\n          -  Negative urine screening.\n\n          -  No clinically significant abnormalities of electrocardiogram.\n\n        Prior Medication:\n\n        Allowed:\n\n        Antiretroviral therapy providing patient has been on a stable, unchanged regimen for 8\n        weeks prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Acute opportunistic infection or other significant concurrent illness that would\n             preclude participation for the required 36 days.\n\n          -  Unable to swallow oral solution.\n\n          -  Obesity greater than 25% of ideal body weight.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Rifampin.\n\n          -  Rifabutin.\n\n          -  Phenobarbital.\n\n          -  Phenytoin.\n\n          -  Carbamazepine.\n\n          -  Digoxin.\n\n          -  Warfarin.\n\n          -  Midazolam.\n\n          -  Triazolam.\n\n          -  Terfenadine.\n\n          -  Astemizole.\n\n          -  Cisapride.\n\n          -  H2 blockers.\n\n          -  Omeprazole.\n\n          -  Continual antacids.\n\n          -  Didanosine.\n\n          -  Any medication known to affect absorption, metabolism or excretion of imidazole or\n             azole compounds.\n\n        Patients with the following prior symptoms and conditions are excluded:\n\n          -  Previous hypersensitivity to azole antifungals.\n\n          -  History of surgical procedure that may interfere with absorption of itraconazole.\n\n          -  History of significant blood loss in the previous 30 days.\n\n        Prior Medication:\n\n        Excluded:\n\n        Excluded within 15 days prior to study entry:\n\n          -  Rifampin.\n\n          -  Rifabutin.\n\n          -  Phenobarbital.\n\n          -  Phenytoin.\n\n          -  Carbamazepine.\n\n          -  Digoxin.\n\n          -  Warfarin.\n\n          -  Midazolam.\n\n          -  Triazolam.\n\n        Excluded within 8 weeks prior to study entry:\n\n          -  Change in antiretroviral therapy.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Patients who chew tobacco or regularly smoke more than 10 cigarettes per day."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002370", 
            "org_study_id": "254B"
        }, 
        "intervention": {
            "intervention_name": "Itraconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "keyword": [
            "Itraconazole", 
            "Administration, Oral", 
            "Antifungal Agents", 
            "Acquired Immunodeficiency Syndrome", 
            "Drug Administration Schedule"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14215"
                }, 
                "name": "Erie County Med Ctr / Pharmacy D"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002370"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen, LP", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {
        "Erie County Med Ctr / Pharmacy D": "42.886 -78.878"
    }
}